-+ 0.00%
-+ 0.00%
-+ 0.00%

Biomea Fusion Inc. Announces 2026 Strategy Focusing on Advancing Icovamenib and BMF-650 Clinical Programs, Initiating Phase II Trials in Type 2 Diabetes and Continuing Oral GLP-1 Candidate Development

Reuters·01/12/2026 13:00:15

Please log in to view news